|Systematic (IUPAC) name|
|Molar mass||416.753 g/mol[[Script error: No such module "String".]]|
|Script error: No such module "collapsible list".|
S-23 is an investigational selective androgen receptor modulator (SARM) developed by GTx Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|40px||This drug article relating to the genito-urinary system is a stub. You can help ssf by expanding it.|
- Marhefka CA, Gao W, Chung K, Kim J, He Y, Yin D, Bohl C, Dalton JT, Miller DD. Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. Journal of Medicinal Chemistry. 2004 Feb 12;47(4):993-8. PMID 14761201
- Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT. Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology. 2009 Jan;150(1):385-95. PMID 18772237